19.900USD+19.900After-hours 07/30, 20:00 (ET)
2.04BMarket Cap
LossP/E TTM
Viridian Therapeutics Inc
Key Figures
19.550Open
20.005High
1.22MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.19%Turnover Ratio
19.880Prev. Close
19.290Low
16.89MTurnover
LossP/E Static
4.04P/B
0.00%Div Yield TTM
-49.74%ROA
34.29052wk High
0.74Volume Ratio
-269.95MNet Profit
102.46MShares
-3.9978EPS TTM
0.88Beta
-78.43%ROE
13.18052wk Low
3.60%Amplitude
100.00%Gross Margin
2.04BMarket Cap
2.35Reward/Risk
3.23%Risk Rate
Currency: USD Updated: 2026-07-30 Key Insights
Viridian Therapeutics Inc's fundamentals are relatively healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 58 out of 384 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 35.33.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Viridian Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Viridian Therapeutics Inc Highlights
StrengthsRisks
Viridian Therapeutics Inc News
More news coming soon, stay tuned...
Earnings Forecast
Strong Buy
Buy
Hold
Sell
Strong Sell
Viridian Therapeutics Inc
VRDN
17
Ionis Pharmaceuticals Inc
IONS
27
Indicators
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Viridian Therapeutics Inc Info
Viridian Therapeutics, Inc. is a biopharmaceutical company focused on engineering and developing potential medicines for patients with serious and rare diseases. The Company is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The Company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of veligrotug in patients with active and chronic TED. It is also conducting two global Phase 3 clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of VRDN-003 in patients. Its advanced program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED. In addition to its TED portfolio, the Company is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.
Ticker SymbolVRDN
CompanyViridian Therapeutics Inc
CEOMahoney (Stephen)
Websitehttps://www.viridiantherapeutics.com/
Shareholders
FAQs
What is the current price of Viridian Therapeutics Inc (VRDN)?
The current price of Viridian Therapeutics Inc (VRDN) is 19.89.
What is the symbol of Viridian Therapeutics Inc?
The ticker symbol of Viridian Therapeutics Inc is VRDN.
What is the 52-week high of Viridian Therapeutics Inc?
The 52-week high of Viridian Therapeutics Inc is 34.29.
What is the 52-week low of Viridian Therapeutics Inc?
The 52-week low of Viridian Therapeutics Inc is 13.18.
What is the market capitalization of Viridian Therapeutics Inc?
The market capitalization of Viridian Therapeutics Inc is 2.04B.
Is Viridian Therapeutics Inc (VRDN) currently rated as Buy, Hold, or Sell?
According to analysts, Viridian Therapeutics Inc (VRDN) has an overall rating of Buy, with a price target of 35.33.
What is the Earnings Per Share (EPS TTM) of Viridian Therapeutics Inc (VRDN)?
The Earnings Per Share (EPS TTM) of Viridian Therapeutics Inc (VRDN) is -4.04.
